CLINICAL SAFETY OF 311C90 - AGGREGATED DATA FROM PATIENTS AND VOLUNTEERS TO DATE

The tolerability of 311C90, a novel, selective and highly effective 5- HT1D receptor agonist in development for the acute treatment of migrai ne, has been evaluated in a number of clinical pharmacology and patien t studies across the dose range 1-50 mg. 311C90 has been well tolerate d across the entire dose range and no clinically relevant changes in r outine laboratory parameters, blood pressure or ECG recordings have be en observed, Adverse experiences reported are generally dose related, mild to moderate and resolve spontaneously, Chest-related symptoms occ ur infrequently and the cardiovascular safety profile of 311C90 is con sidered particularly favourable, 311C90, therefore, possesses a desira ble safety profile which is well suited to broad-based outpatient admi nstration.